1921
Volume 76, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The fixed dose combination of atovaquone and proguanil hydrochloride, marketed under the trade name Malarone™, is the most recently approved agent in North America for the prevention and treatment of chloroquine- and multi-drug resistant malaria. In both adult and pediatric populations, atovaquone-proguanil demonstrates consistently high protective efficacy against and in treatment trials, cure rates exceed 93%. Only a handful of genetically confirmed treatment failures have been reported to date. Atovaquone-proguanil has an excellent safety profile during both prophylaxis and treatment courses, with severe adverse events rarely reported. This topical review will examine the evidence behind the current indications for use of atovaquone-proguanil, and will summarize the current body of literature surrounding safety and tolerability.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2007.76.208
2007-02-01
2019-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/76/2/0760208.html?itemId=/content/journals/10.4269/ajtmh.2007.76.208&mimeType=html&fmt=ahah

References

  1. Kish MA, 2001. Guide to development of practice guidelines. Clin Infect Dis 32 : 851–854. [Google Scholar]
  2. Briggs GG, Freeman RK, Yaffe SJ, 2005. Atovaquone-proguanil. Mitchell CW, ed. Drugs in Pregnancy and Lactation. Seventh edition. Baltimore, MD: Lippincott, Williams, & Wilkins, 128–130, 1349–1352.
  3. Centers for Disease Control and Prevention, 2005. Health information for international travel 2005–2006. www.cdc.gov/travel/yb Accessed July 17, 2006.
  4. Committee to Advise on Tropical Medicine and Travel (CATMAT), 2004. Canadian recommendations for the prevention and treatment of malaria among international travelers. Can Comm Dis Rep 30S : 1–62. [Google Scholar]
  5. The Medical Letter, 2004. Drugs for parasitic infections. Med Lett Drug Ther August 2004 : 1–12. [Google Scholar]
  6. GlaxoSmithKline Inc, 2004. Malarone. GSK Product Monograph. Research Triangle Park, NC, GSK.
  7. Schlagenhauf P, Beallor C, Kain KC, 2004. Chemoprophylaxis of malaria. Keystone JS, Kozarsky PE, Freedman DO, Nothdurft HD, Connor BA, eds. Travel Medicine. Philadelphia, PA: Elsevier Science, 137–156.
  8. Centers for Disease Control and Prevention, 2005. Treatment of malaria (guidelines for clinicians). www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm Accessed July 17, 2006.
  9. Shanks GD, Gordon DM, Klotz FW, Aleman G, Oloo A, Sadie D, Scott T, 1998. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 27 : 494–499. [Google Scholar]
  10. Sukwa TY, Mulenga M, Chisdaka N, Roskell N, Scott T, 1999. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/ proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 60 : 521–525. [Google Scholar]
  11. Lell B, Luckner D, Ndjave M, Scott T, Kremsner P, 1998. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 351 : 709–713. [Google Scholar]
  12. Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, Lell B, Que J, Miller G, Kremsner P, 2002. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 35 : 1147–1154. [Google Scholar]
  13. van der Berg JD, Duvenage CSJ, Roskell NS, Scott TR, 1999. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa. Clin Ther 21 : 741–749. [Google Scholar]
  14. Hogh B, Clarke PD, Camus D, Nothdurft H, Overbosch D, Gunther M, Joubert I, Kain K, Shaw D, Roskell N, Chulay J, Malarone International Study Team, 2000. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travelers: a randomized, double-blind study. Lancet 356 : 1888–1894. [Google Scholar]
  15. Overbosch D, Schilthuis H, Bienzle U, Behrens R, Kain K, Clarke P, Toovey S, Knobloch J, Nothdurft H, Shaw D, Roskell N, Chulay J, Malarone International Study Team, 2001. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: Results from a randomized, double-blind study. Clin Infect Dis 33 : 1015–1021. [Google Scholar]
  16. Ling J, Baird JD, Fryauff DJ, Sismadi P, Bangs M, Lacy M, Barcus M, Gramzinski R, Maguire J, Kumusumangsih M, Miller G, Jones T, Chulay J, Hoffmann S, Naval Medical Research Unit 2 Clinical Trial Team, 2002. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 35 : 825–833. [Google Scholar]
  17. Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, Roskell N, Hedgley C, De Boever E, Miller G, International Malarone Study Team, 2004. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: Results of an international, randomized, open-label study. Clin Infect Dis 38 : 1716–1723. [Google Scholar]
  18. Shanks GD, 1999. New options for the prevention and treatment of malaria: Focus on the role of atovaquone and proguanil hydrochloride. J Travel Med 6 (Suppl 1): 1. [Google Scholar]
  19. Looareesuwan S, Wilairatana P, Glanarongran R, Indravijit K, Supeeranontha L, Chinnapha S, Scott T, Chulay J, 1999. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 93 : 637–640. [Google Scholar]
  20. Povinelli L, Monson TA, Fox BC, Parise ME, Morrissey JM, Vaidya AB, 2003. Plasmodium vivax malaria in spite of atovaquone/proguanil (Malarone) prophylaxis. J Travel Med 10 : 353–355. [Google Scholar]
  21. Mali S, Parise ME, 2005. Provisional Data Report on Malaria Surveillance and Use of Antimalarial Chemoprophylaxis January–December 2004. Atlanta: Centers for Disease Control and Prevention, 1–20.
  22. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner P, 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 347 : 1511–1514. [Google Scholar]
  23. de Alencar FE, Cerutti C, Durlacher RR, Boulos M, Alves FP, Milhous W, Pang L, 1997. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 175 : 1544–1547. [Google Scholar]
  24. Mulenga M, Sukwa TY, Canfield CJ, Hutchinson DB, 1999. Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther 21 : 841–852. [Google Scholar]
  25. Bustos DG, Canfield CJ, Canet-Miguel E, Hutchinson DB, 1999. Atovaquone proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 179 : 1587–1590. [Google Scholar]
  26. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield C, Hutchinson D, 1999. Efficacy and safety of atovaquone-proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 60 : 526–532. [Google Scholar]
  27. Bouchaud O, Monlun E, Muanza K, Fontanet A, Scott T, Goetschel A, Chulay J, Le Bras J, Danis M, Le Bras M, Coulard J, Gentilini M, 2000. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: A randomized comparative trial. Am J Trop Med Hyg 63 : 274–279. [Google Scholar]
  28. van Vugt M, Leonardi E, Phaipun L, Slight T, Thway K, McGready R, Brockman A, Villegas L, Looareesuwan S, White N, Nosten F, 2002. Treatment of uncomplicated multi-drug resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 35 : 1498–1504. [Google Scholar]
  29. Anabwani G, Canfield CJ, Hutchinson D, 1999. Combination atovaquone and proguanil hydrochloride versus halofantrine for treatment of acute Plasmodium falciparum malaria in children. Ped Infect Dis J 18 : 456–461. [Google Scholar]
  30. Bormann S, Faucher JF, Bagaphou T, Missinou M, Binder R, Pabisch S, Rezbach P, Matsiegui PB, Lell B, Miller G, Kremsner P, 2003. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clin Infect Dis 37 : 1441–1447. [Google Scholar]
  31. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ, 1996. Clinical studies of atovaquone alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54 : 62–66. [Google Scholar]
  32. Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R, Basri H, Sismadi P, Miller GB, Chulay JD, Fryauff DJ, Hoffman SL, Baird JK, 2002. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 35 : e92–e95. [Google Scholar]
  33. Radloff PD, Philipps J, Hutchinson D, Kremsner PG, 1996. Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P.malariae malaria. Trans R Soc Trop Med Hyg 90 : 682. [Google Scholar]
  34. Fivelman QL, Butcher GA, Adagu IS, Warhurst D, Pasvol G, 2002. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malaria J 1 : 1–4. [Google Scholar]
  35. Schwartz E, Bujanover S, Kain KC, 2003. Genetic confirmation of atovaquone-proguanil resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 37 : 450–451. [Google Scholar]
  36. Schwobel B, Alifrangis M, Salanti A, Jelinek T, 2003. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: Rapid detection of codon 268 polymorphisms in the cytochrome b as a potential in vivo resistance marker. Malaria J 2 : 5–11. [Google Scholar]
  37. David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB, 2003. Atovaquone/proguanil resistance in Africa: A case report. Scand J Infect Dis 35 : 897–898. [Google Scholar]
  38. Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar M, Lindegardh N, Berezcky S, Bjorkman A, 2003. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 326 : 628–629. [Google Scholar]
  39. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T, 2004. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malaria J 3 : 14–16. [Google Scholar]
  40. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferi A, Laferi H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, de Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J, European Network on Surveillance of Imported Infectious Diseases, 2004. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 190 : 1541–1546. [Google Scholar]
  41. Kuhn S, Gill MJ, Kain KC, 2005. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune North American traveler to West Africa. Am J Trop Med Hyg 72 : 407–409. [Google Scholar]
  42. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ, 1997. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol 61 : 518–530. [Google Scholar]
  43. Gillotin C, Mamet JJP, Veronese L, 1999. Lack of pharmacokinetic interaction between atovaquone and proguanil. Eur J Clin Pharmacol 55 : 311–315. [Google Scholar]
  44. Thapar MM, Ashton M, Lindegardh N, Bergqvist Y, Nivelius S, Johansson I, Bjorkman A, 2002. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol 58 : 19–27. [Google Scholar]
  45. Hudson AT, Dickins M, Ginger CD, Gutteridge WE, Holdich T, Hutchinson DB, Pudney M, Randall AW, Latter VS, 1991. A potent broad spectrum antiinfective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 17 : 427–435. [Google Scholar]
  46. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB, 1999. Resistance mutations reveal the atovaquone binding domain of cytochrome b in malaria parasites. Mol Microbiol 33 : 704–711. [Google Scholar]
  47. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P, 1999. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 60 : 831–836. [Google Scholar]
  48. Fairley NH, 1946. Researches on paludrine (M.4888) in malaria: an experimental investigation undertaken by the LHQ Medical Research Unit (AIF), Cairns, Australia. Trans R Soc Trop Med Hyg 40 : 105–151. [Google Scholar]
  49. Berman JD, Nielsen R, Chulay JD, Dowler M, Kain KC, Kester KE, Williams J, Whelen AC, Shmuklarsky MJ, 2001. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 95 : 429–432. [Google Scholar]
  50. Fry M, Pudney M, 1992. Site of action of the antimalarial hydroxy-naphthoquinone, 2-[trans-4-(4′-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43 : 1545–1553. [Google Scholar]
  51. Srivastava IK, Rottenberg H, Vaidya AB, 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malaria parasite. J Biol Chem 272 : 3961–3966. [Google Scholar]
  52. Pudney M, Gutteridge W, Zeman A, Dickins M, Woolley JL, 1999. Atovaquone and proguanil hydrochloride: a review of nonclinical studies. J Travel Med 6 (Suppl 1): S8–12. [Google Scholar]
  53. Srivastava IK, Vaidya AB, 1999. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 43 : 1334–1339. [Google Scholar]
  54. Canfield CJ, Pudney M, Gutteridge WE, 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80 : 373–381. [Google Scholar]
  55. Gay F, Bustos D, Traore B, 1997. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: Comparison between African and Asian strains. Am J Trop Med Hyg 56 : 315–317. [Google Scholar]
  56. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM, 1990. The pharmacokinetics and activation of proguanil in man: Consequences of variability in drug metabolism. Br J Clin Pharmacol 30 : 595–598. [Google Scholar]
  57. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q, 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44 : 2100–2108. [Google Scholar]
  58. Reynolds MG, Roos DS, 1998. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J Biol Chem 273 : 3461–3469. [Google Scholar]
  59. Steffen R, Heusser R, Machler R, Bruppacher R, Naef U, Chen D, Hofmann AM, Somaini B, 1990. Malaria chemoprophylaxis among European tourists in tropical Africa: Use, adverse reactions, and efficacy. Bull World Health Org 68 : 313–322. [Google Scholar]
  60. Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, Parise M, Odero M, Waiyaki P, 2001. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 8 : 167–172. [Google Scholar]
  61. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB, 1999. Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 60 : 533–541. [Google Scholar]
  62. Erikkson B, Bjorkman A, Keiau M, 1991. How safe is proguanil? A post-marketing investigation of side effects. Scand J Infect Dis 23 : 489–493. [Google Scholar]
  63. Petersen E, 2003. The safety of atovaquone-proguanil in long-term malaria prophylaxis of non-immune adults. J Travel Med 10 (Suppl 1): S13–S15. [Google Scholar]
  64. Overbosch D, 2003. Post-marketing surveillance: Adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. J Travel Med 10 (Suppl 1): S16–S20. [Google Scholar]
  65. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R, 2003. Tolerability of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa: Multicenter, randomized, double-blind, four arm study. BMJ 329 : 1078–1081. [Google Scholar]
  66. Simons R, Valk P, Krul AJ, 2005. Malaria prophylaxis for aircrew: Safety of atovaquone/proguanil in health volunteers under aircraft cabin pressure conditions. J Travel Med 12 : 210–216. [Google Scholar]
  67. Emberger M, Lechner AM, Zelger B, 2003. Stevens-Johnson syndrome associated with malarone antimalarial prophylaxis. Clin Infect Dis 37 : e5–e7. [Google Scholar]
  68. Grieshaber M, Lammli J, Marcus L, 2005. Acute hepatitis and atovaquone/proguanil. J Trav Med 12 : 289–290. [Google Scholar]
  69. Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, Chongsuphajaisiddhi T, Sadler BM, Hussein Z, Canfield CJ, Hutchinson D, 1998. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 92 : 201–206. [Google Scholar]
  70. Thybo S, Gjorup I, Ronn A, Meyrowitsch D, Bygberg IC, 2004. Atovaquone-proguanil (Malarone): An effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. J Travel Med 11 : 220–224. [Google Scholar]
  71. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC, 1993. Long-term malaria prophylaxis with weekly mefloquine. Lancet 341 : 848–851. [Google Scholar]
  72. Gozal D, Hengy C, Fadat G, 1991. Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance. Antimicrob Agents Chemother 35 : 373–376. [Google Scholar]
  73. Saraux A, Taelman H, Van der Stuyft P, Dabis F, 1992. Effectiveness of long-term malaria chemoprophylaxis among French expatriates residing in Rwanda. Ann Soc Belg Med Trop 72 : 225–227. [Google Scholar]
  74. GlaxoSmithKline Inc, 1999. Mepron Brand of Atovaquone Suspension. GSK Product Monograph. Research Triangle Park, NC: GSK.
  75. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH Jr, Eng R, Hooton TM, Kerkering TM, Schutz M, van der Horst C, Hafner R, 1998. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 339 : 1889–1895. [Google Scholar]
  76. Hughes WT, Dankar WM, Yogev R, Huang S, Paul ME, Flores MA, Kline MW, Wei LJ, 2005. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 40 : 136–145. [Google Scholar]
  77. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA, Scott J, Marina R, Caldwell P, 1999. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180 : 369–376. [Google Scholar]
  78. Tracy J, Webster L, 1996. Drugs used in the chemotherapy of malaria. Hardman J, Gilman A, Limbird C, eds. Goodman and Gilman’s the Pharmacologic Basis of Therapeutics. New York: McGraw-Hill, 965–985.
  79. The Medical Letter, 2000. Atovaquone/proguanil (Malarone) for malaria. Med Lett Drug Ther 42 : 109–111. [Google Scholar]
  80. Lee BL, Sadler B, Goldstein D, Chambers HF, 1996. Atovaquone inhibits the glucuronidation and increases the plasma concentration of zidovudine. Clin Pharmacol Ther 59 : 14–21. [Google Scholar]
  81. Taburet AM, Singlas E, 1996. Drug interactions with antimalarial drugs. Clin Pharmacokinet 30 : 385–401. [Google Scholar]
  82. Van de Poll ME, Relling MV, Schuetz EG, Harrison PL, Hughes W, Flynn PM, 2001. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 47 : 467–472. [Google Scholar]
  83. Ngo LY, Yogev R, Dankner WM, Hughes WT, Burchett S, Xu J, Sadler B, Unadkat JD, 1999. Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 43 : 1516–1519. [Google Scholar]
  84. Hughes W, Dorenbaum A, Yogev R, Beauchamp B, Xu J, Mc-Namara J, Moye J, Purdue L, van Dyke R, Rogers M, Sadler B, 1998. Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Antimicrob Agents Chemother 42 : 1315–1318. [Google Scholar]
  85. White A, LaFon S, Rogers M, Andrews E, Brown N, 1995. Clinical experience with atovaquone in a treatment investigational new drug protocol for Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 9 : 280–285. [Google Scholar]
  86. Phillips-Howard PA, Wood D, 1996. The safety of antimalarial drugs in pregnancy. Drug Saf 14 : 131–145. [Google Scholar]
  87. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F, 2003. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 59 : 545–552. [Google Scholar]
  88. McGready R, Keo NK, Villegas L, White NJ, Looareesuwan S, Nosten F, 2003. Artesunate-atovaquone-proguanil rescue treatment of multidrug resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R Soc Trop Med Hyg 97 : 592–594. [Google Scholar]
  89. McGready R, Ashley EA, Moo E, Cho T, Barends M, Hutagalung R, Looareesuwan S, White NJ, Nosten F, 2005. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 192 : 846–853. [Google Scholar]
  90. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R, 1973. Transection of the esophagus for bleeding oesophageal varices. Br J Surg 60 : 646–654. [Google Scholar]
  91. Boots M, Phillips M, Curtis JR, 1982. Megaloblastic anemia and pancytopenia due to proguanil in patients with chronic renal failure. Clin Nephrol 18 : 106–108. [Google Scholar]
  92. Bryan JP, 2006. Cost considerations for malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. Am J Trop Med Hyg 75 : 416–420. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.76.208
Loading
/content/journals/10.4269/ajtmh.2007.76.208
Loading

Data & Media loading...

  • Received : 20 Jul 2006
  • Accepted : 02 Oct 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error